Sabby Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Sabby Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,189,700	Closed	-$10.2M	–	206
2021 Q4	$10.2M	Buy	2,189,700 +491,593	+29%	+$3.05M	1.48%	11
2021 Q3	$13M	Buy	1,698,107 +500,131	+42%	+$4.24M	1.75%	11
2021 Q2	$11.6M	Buy	1,197,976 +133,043	+12%	+$1.06M	1.64%	8
2021 Q1	$8.81M	Buy	+1,064,933	New	+$11.2M	1.71%	9
2020 Q4	–	Sell	-606,298	Closed	-$4.87M	–	163
2020 Q3	$6.76M	Buy	+606,298	New	+$5.55M	1.01%	21
2020 Q2	–	Sell	-287,386	Closed	-$1.1M	–	134
2020 Q1	$529K	Buy	287,386 +260,208	+957%	+$749K	0.22%	39
2019 Q4	$92K	Buy	+27,178	New	+$64.8K	0.03%	63
2019 Q1	–	Sell	-84,536	Closed	–	–	143
2018 Q4	$0	Buy	+84,536	New	+$276K	﹤0.01%	151
2017 Q3	–	Sell	-17,300	Closed	-$35K	–	221
2017 Q2	$35K	Buy	+17,300	New	+$33.8K	﹤0.01%	205
2016 Q4	–	Sell	-20,986	Closed	-$162K	–	338
2016 Q3	$162K	Sell	20,986 -232,819	-92%	-$1.57M	0.01%	276
2016 Q2	$1.42M	Sell	253,805 -125,995	-33%	-$805K	0.07%	133
2016 Q1	$2.04M	Buy	379,800 +79,800	+27%	+$464K	0.1%	97
2015 Q4	$2.61M	Buy	300,000 +132,936	+80%	+$1.12M	0.14%	104
2015 Q3	$1.4M	Buy	+167,064	New	+$2.66M	0.06%	202
2014 Q1	–	Sell	-222,026	Closed	-$1.8M	–	281
2013 Q4	$1.8M	Buy	+222,026	New	+$1.95M	0.11%	91

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Sabby Management's SRNE Position: Q1 2022 in Review

Sabby Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2022, closing a stake of 2,189,700 shares — an estimated $10.2M sold.

Sabby Management first reported a position in SRNE in Q4 2013 and held it in 15 quarters. The position peaked at $13M in Q3 2021. 235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

Sabby Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
Sabby Management sold 2,189,700 Sorrento Therapeutics, Inc. shares in Q1 2022, an estimated $10.2M.
Sabby Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2013 and held it in 15 quarters.
Sabby Management's Sorrento Therapeutics, Inc. position peaked at $13M in Q3 2021.
235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.